"rationale","versionIdentifier","instanceType","uuid:ID","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","StudyVersion","b5295106-8a2a-466d-b38d-d861d47148a8","StudyVersion_1"
